Robert Smith MD Medical Director, Adult Liver Transplant Program Department of Gastroenterology and Hepatology Geisinger Medical Center Danville, PA
|
|
- Mervyn Goodwin
- 7 years ago
- Views:
Transcription
1 Robert Smith MD Medical Director, Adult Liver Transplant Program Department of Gastroenterology and Hepatology Geisinger Medical Center Danville, PA
2 Disclosures: Pharmaceutical Speaker Bureau Participant for: Salix Vertex Genentech *This talk contains no discussion of Pharmacologic agents
3 > 18,000 people are UNOS listed for orthotropic liver transplant (OLTX) Donor pool has remained flat at 6000 organs/year Approximately 1/3 of patients on the wait list die there or are de-listed Only 150 non-pediatric living related donor transplants are done nationally Approximately 600 OLTX are done annually in PA (10%)
4 1973: Dr. Starzl performs the first successful liver transplantation 1982: Medicare approves liver transplantation as a nonexperimental reimbursable treatment for end stage liver disease (transplant programs blossomed ) 1987: To formalize sold organ allocation the US Government established the OPTN (organ procurement and transplantation network)
5
6
7
8 Initially Informal: sickest patient first wait time on list a factor Increasing demand for organs and lack of standardization led to a CTP-based scoring and listing system
9 Calculator: Child Pugh classification for severity of liver disease Encephalopathy None (1 point) Grade 1: Altered mood/confusion (2 points) Grade 2: Inappropriate behavior, impending stupor, somnolence (2 points) Grade 3: Markedly confused, stuporous but arousable (3 points) Grade 4: comatose/unresponsive (3 points) Ascites Absent (1 point) Slight (2 points) Moderate (3 points) Bilirubin < 2 mg/dl (1 point) 2-3 mg/dl (2 points) > 3 mg/dl (3 points) Albumin > 3.5 g/dl (1 point) g/dl (2 points) < 2.8 g/dl (3 points) (cont d)
10 Prothrombin time prolongation Less than 4 seconds above control/inr < 1.7 (1 point) 4-6 seconds above control/inr (2 points) More than 6 seconds above control/inr > 2.3 (3 points) Total Criteria Point Count: 0 Child Pugh Score Interpretation 5-6 points: Child class A 7-9 points: Child class B points: Child class C
11 Status 1: FHF, Primary Graft Non-Function, etc. essentially same today Status 2A: CTP >10, not expected to live 7 days (in ICU) Status 2B: CTP >10, expected to live > 7 days Status 3: CTP >7 (minimal listing criteria) Criteria were very subjective and major component determining allocation was wait time
12 In 1998 HHS stated a new allocation methodology based on scientifically validated medical criteria, deemphasizing wait time, needed to be developed and implemented
13 OPTN response was to us an existent model known as the Mayo End-Stage Liver Disease Model, now Model For End-Stage Liver Disease, or the MELD Score (originally predicted 3 month survival post- TIPS)
14 MELD = ( LN (creatinine) = x LN (bilirubin) x Ln (INR ) * continuous scoring from 7 40 ** creat. caps at 4.0
15 Implemented in 2002 Status 1 remained unchanged All other patients listed by MELD score and blood type Regional Review Boards (RRB s) were established to review cases where MELD was felt not predictive of true mortality and possibly grant exception points
16
17 Very accurate at predicting 30, 90, 180, and 360 day mortality (validated by multiple analysis) Can be updated on a daily basis Has eliminated wait time as an important variable except in ties Decreases deaths on the wait list
18 Does not factor in severity of complications of portal hypertension (presumably RRB s can address this regionally) Creates significant variation in scores at time of transplant (e.g. 48% of region 6 recipients had scores in the range, but only 20% in region 1)
19
20 Standardized formula for patients with Stage II hepato-cellular CA (HCC) used nationally All other indications for requested exception points non-standardized with resultant large variation in number of patients who receive points and number of exception points allocated
21
22
23 So What can be done to level the playing field?
24 RRB Regional Inequities: Standardize criteria Nationally (as has been done for HCC) for 12 most common indications for exception point requests (would leave a relatively small number of outlier cases requiring actual RRB review)
25 Major Problem = No consensus on goal: Direct organs to regions with high MELD scores at time of transplant? Direct organs to minority/poor patients? Are harvested organs a national, regional, or local resource? (all hotly debated)
26 MELD re-weighting, add other parameters ( MELDNA, MELD-D, & SHARE I5 ) Regional or even National sharing at a specific MELD threshold ( share is concept) Expanding the donor pool (ECD, opt-in vs. opt-out concept) Net benefit model (statistically calculate the difference between 5 year wait list mortality and expected post-transplant survival (SRTR is robust enough to support this) All of these proposals are being studied Each has theoretical benefits and pitfalls No consensus exists for any of these models At this juncture regional sharing (which could be initiated differently in each region) has the best chance of reaching a consensus
27 Regional based If an OPO within a region harvests a liver, but has no recipient to match with a MELD > 15, the organ is offered to the rest of the OPO s within that region Statistically, at a MELD of 15, the risks of transplant outweigh the potential benefit There is growing consensus to nationalize SHARE 15
28 Each region would set a MELD threshold for sharing outside the harvesting OPO that statistically maximizes benefit in that region Geographic considerations that might significantly increase cold ischemia and time would have to considered An accepted sharing threshold would be developed (difference of 2 MELD points required between local and non-local candidates)
29 Current system serves the majority of patients with ESLD WELC Standardization of RRB exception point criteria long over due Regional inequities will likely drive acceptance of some form of MELD revision and some for of expanded sharing Every effort to expand the donor pool should be explored
Evaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
More information*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS
The shortage of kidney donors and the ever-increasing waiting list has prompted the transplant community to look at different types of organ donors to meet the needs of our patients on the waiting list.
More informationLIVER TRANSPLANTATION IN ALAGILLE SYNDROME
LIVER TRANSPLANTATION IN ALAGILLE SYNDROME Ronald J. Sokol, MD Children s Hospital Colorado University of Colorado School of Medicine Treatment of Liver Disease in Improve bile flow ALGS Ursodeoxycholic
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationCenter Activity (07/01/2009-06/30/2010) Center Region United States Tables for More Information
Program Summary Center Activity (07/01/2009-06/30/2010) Center Region United States Tables for More Information Deceased donor transplants (n=number) 0 169 0 07C,08C,09C On waitlist at start (n) 0 0 0
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationCandidates about Multiple Listing and Waiting Time Transfer
TA L K I N G A B O U T T R A N S P L A N TAT I O N Questions & A n s we r s for Transplant Candidates about Multiple Listing and Waiting Time Transfer U N I T E D N E T W O R K F O R O R G A N S H A R
More informationQuestions and Answers for Transplant Candidates about the New Kidney Allocation System
TA L K I N G A B O U T T R A N S P L A N TAT I O N U N I T E D N E T W O R K F O R O R G A N S H A R I N G Questions and Answers for Transplant Candidates about the New Kidney Allocation System United
More informationThe New Kidney Allocation System: Resources for Protocols and Processes webinar.
The New Kidney Allocation System: Resources for Protocols and Processes webinar. 1 Speakers for the webinar are: Dr. Richard Formica Associate Professor of Medicine and Surgery, Yale University School
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationDemystifying Transplant Performance Reviews. Robyn Zernhelt Performance Analyst
Demystifying Transplant Performance Reviews Robyn Zernhelt Performance Analyst Pre-Assessment Transplant Performance Reviews The PAIS reviews which transplant programs? 1. Kidney, Pancreas, Intestine 2.
More informationThe State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
More informationOPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA.
OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA Summary I. Action Items for Board Consideration The Board is asked to approve
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationDavid Axelrod, MD, MBA Associate Professor of Surgery Section Chief Solid Organ Transplantation Dartmouth Hitchcock Medical Center
David Axelrod, MD, MBA Associate Professor of Surgery Section Chief Solid Organ Transplantation Dartmouth Hitchcock Medical Center Economic analysis team Mark Schnitzler, Ph.D. Krista Lentine MD, Ph.D.
More informationImpact of MELD-Based Allocation on End-Stage Renal Disease After Liver Transplantation
American Journal of Transplantation 2011; 11: 2372 2378 Wiley Periodicals Inc. C Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2011.03703.x
More informationDavid Axelrod, MD, MBA. Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center
David Axelrod, MD, MBA Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center Owner of XynManagement which produces software to track and improve
More informationTHE BENEFITS OF LIVING DONOR KIDNEY TRANSPLANTATION. feel better knowing
THE BENEFITS OF LIVING DONOR KIDNEY TRANSPLANTATION feel better knowing your choice will help create more memories. Methods of Kidney Donation Kidneys for transplantation are made available through deceased
More informationNew Kidney Allocation and What it Means to Your Transplant Center and Your Patients
New Kidney Allocation and What it Means to Your Transplant Center and Your Patients Alexander Wiseman, M.D. Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationSaint Francis Kidney Transplant Program Issue Date: 6/9/15
Kidney Transplant Candidate Informed Consent Education Here are educational materials about Kidney Transplant. Please review and read these before your evaluation visit. The RN Transplant Coordinator will
More informationEffect of Pretransplant Serum Creatinine on the Survival Benefit of Liver Transplantation
LIVER TRANSPLANTATION 15:1808-1813, 2009 ORIGINAL ARTICLE Effect of Pretransplant Serum Creatinine on the Survival Benefit of Liver Transplantation Pratima Sharma, 1 Douglas E. Schaubel, 2,4 Mary K. Guidinger,
More informationHepatocellular Carcinoma: What the hepatologist wants to know
Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationCharacterisation of co-morbidities in patients with alcoholic liver disease and engaging them in treatment.
Characterisation of co-morbidities in patients with alcoholic liver disease and engaging them in treatment. Khairunnessa Rahman, Dheeraj Shukla, Leigh Dahlenburg, Andrew Bailey, Robert Gribble, Paul Haber
More informationAcute on Chronic Liver Failure: Current Concepts. Disclosures
Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures
More informationWhere Will my New Kidney Come From?
Where Will my New Kidney Come From? The Organ Shortage There is a severe shortage of organs for transplant. This means that the wait for a kidney transplant can be many years. The UW Transplant Program
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
More informationUser Guide. A. Program Summary B. Waiting List Information C. Transplant Information
User Guide This report contains a wide range of useful information about the pancreas transplant program at Saint Louis University Hospital (MOSL). The report has three main sections: A. Program Summary
More informationKidney Transplantation and Cancer - A Review
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: renal_kidney_transplantation 4/1980 4/2016 4/2017 4/2016 Description of Procedure or Service A kidney transplant
More informationR. Duane Davis, MD MBA
R. Duane Davis, MD MBA Reasons that health systems want a flourishing lung transplant program Profitability $35-90 K/ case transplant admission- almost 10 million in profit Potential Growth demand >>>
More informationIllinois. Blue Distinction Centers for Transplants
Blue Distinction Centers for Transplants Illinois INSTITUTION University of Chicago Medical Center 5841 S. Maryland Avenue Chicago, 60637-1470 (773) 702.1000 TIN 36-3488183N www.uchospitals.edu TYPE OF
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationTransplant Coordinator
Have you signed your organ donor card? Hearts, kidneys, livers, and lungs can all be transplanted. When you die, one of your organs could help a critically ill patient live a longer life. What I do every
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More informationPreparing for ABO Determination, Reporting and Verification Policy Changes Webinar Script
Our speaker for today s webinar is Theresa Daly. Theresa is the Director of Clinical Operations for the Transplant Hospital at the New York Presbyterian Hospital Columbia University. In this role she oversees
More informationHepatocellular Carcinoma Treatment Decision Tree
Treatment Decision Tree Derek DuBay, MD Assistant Professor of Surgery Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery 1 UAB Liver Tumor Clinic Referrals: 205 996 5970 (phone) 205
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationPartnering With Your Transplant Team
Partnering With Your Transplant Team The Patient s Guide to Transplantation U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration This booklet was prepared for the Health
More informationAlcoholic Hepatitis (Teacher s Guide)
Thomas Ormiston, M.D. Updated 5/5/15 2007-2015, SCVMC Alcoholic Hepatitis (Teacher s Guide) (30 minutes) I. Objectives Recognize the signs and symptoms of alcoholic hepatitis Understand the treatment options
More informationTA L K I N G A B O U T T R A N S P L A N TAT I O N
TA L K I N G A B O U T T R A N S P L A N TAT I O N UNITED NETWORK FOR ORGAN SHARING United Network for Organ Sharing (UNOS) is a private non-profit 501(c)(3) organization that operates the Organ Procurement
More informationBy Avery Comarow FOR PARENTS AND OTHER CAREGIVERS. Why does U.S. News rank children's hospitals?
How and Why: A 2013-14 Best Children's Hospitals FAQ The facts and methodology behind our latest pediatric rankings (cancer survival description corrected). By Avery Comarow Why should anyone care about
More informationEnd Stage Liver Disease: What is New? Marion Peters MD UCSF Berlin 2012
End Stage Liver Disease: What is New? Marion Peters MD UCSF Berlin 2012 Natural History of ESLD Increasing liver fibrosis Development of HCC Chronic liver disease Compensated cirrhosis Decompensated cirrhosis
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationLocoregional Treatment of Hepatocellular Carcinoma. Cory Johnston and Sung Cho HPB Surgery Fellows Providence Portland, Oregon
Locoregional Treatment of Hepatocellular Carcinoma Cory Johnston and Sung Cho HPB Surgery Fellows Providence Portland, Oregon Hepatocellular Carcinoma The 3 rd most common cause of cancer- related death
More informationTA L K I N G A B O U T T R A N S P L A N TAT I O N
TA L K I N G A B O U T T R A N S P L A N TAT I O N Being part of a KPD transplant allowed me to help my husband live a normal life. I was also able to help another family live a normal life. Paired Exchange
More informationAppendix G - Identification and Selection of Studies
FINAL Emergency framework for rationing of blood for massively bleeding patients during a red phase of a Appendix G - Identification and Selection of Studies Inclusion/Exclusion Criteria We included studies
More informationWhat is Health Ethics?
What is Health Ethics? By: Tory Fehrenbacher and Meredith Marston 1. 2. 3. Why is stem cell research ethical? Why is organ donation ethical? Health Ethics: A set of moral principles, beliefs and values
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationDeceased-Donor Renal Transplant Information for patients
Deceased-Donor Renal Transplant Information for patients Exceptional healthcare, personally delivered As part of the work-up for the NHS Blood and Transplant (NHSBT) kidney transplant waiting list, you
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More informationU.S. Senate Finance Committee Hearing on Health Insurance Market Reform
U.S. Senate Finance Committee Hearing on Health Insurance Market Reform Testimony of Pam MacEwan Executive Vice President, Public Affairs and Governance Group Health Cooperative September 23, 2008 Washington,
More informationThe Business of Cellular Therapy and Hematopoietic Stem Cell Transplantation
CHAPTER 2 The Business of Cellular Therapy and Hematopoietic Stem Cell Transplantation Peggy Appel and Richard T. Maziarz Hematopoietic stem cell transplant (HSCT) is a complex process that is associated
More informationCPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD
The blood and marrow transplant field has 15 dedicated CPT codes. These CPT codes can be categorized into three groups: 1. Collection Codes 2. Cell Processing Codes 3. Cell Infusion Codes Collection Codes
More informationNATCO Introductory Education Course Objectives
NATCO Introductory Education Course for the NEW Transplant Professional & Procurement Professional June 12-15, 2015 Tempe Mission Palms Hotel Tempe, AZ Friday, June 12, 2015 SESSION Course Participants
More informationNew Jersey Organ & Tissue Donation
New Jersey Organ & Tissue Donation Contact Hours: 1.0 First Published: May 7, 2013 Course Expires: May 7, 2016 Copyright 2013 by RN.com All Rights Reserved Reproduction and distribution of these materials
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationAASLD PRACTICE GUIDELINE AASLD Practice Guidelines: Evaluation of the Patient for Liver Transplantation
AASLD PRACTICE GUIDELINE AASLD Practice Guidelines: Evaluation of the Patient for Liver Transplantation Karen F. Murray and Robert L. Carithers, Jr. Preamble These recommendations provide a data-supported
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationOMG my LFT s! How to Interpret and Use Them. OMG my LFT s! OMG my LFT s!
How to Interpret and Use Them René Romero, M.D. Clinical Director, Pediatric Hepatology CPG Gastroenterology, Hepatology and Nutrition Emory University School of Medicine Objectives Understand the anatomy
More informationHepatitis C Treatment Advocacy: Ireland. Brian O Mahony
Hepatitis C Treatment Advocacy: Ireland Brian O Mahony Haemophilia and Hepatitis C 775 people with Haemophilia in Ireland 252 people with Haemophilia infected with Hepatitis C before 1992 106 of these
More informationPerspective End-Stage Liver Disease in HIV Disease
Perspective End-Stage Liver Disease in HIV Disease Liver disease is the most common non AIDS-related cause of mortality in HIV-infected patients. HIV-infected patients with chronic liver disease progress
More informationRecruitment and Retention. Nina Parks, MA GI Hepatology Internal Medicine University of California, Davis
Recruitment and Retention Nina Parks, MA GI Hepatology Internal Medicine University of California, Davis Recruitment Plans PI s are expected to identify eligible patients: 1. Clinics 2. Databases (i.e.
More informationGuidance for Industry
Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling U.S. Department of Health and Human Services Food and Drug
More informationKidneys. Kidney Failure4. Transplantation
Kidneys & Kidney Failure4 Transplantation This booklet helps you understand the process of transplantation. It defines the criteria for a donor and the recipient. It also clearly explains the concepts
More informationNational Medicare Readmission. Centers for Medicare and Medicare Services
National Medicare Readmission Findings: Recent Data and Trends Office of Information Products and Data Analytics Office of Information Products and Data Analytics Centers for Medicare and Medicare Services
More informationUnited Network For Organ Sharing. Inquiring Minds Want to Know
United Network For Organ Sharing Inquiring Minds Want to Know Introduction Tommy Trexler Resource Manager, Service Desk Andrea Loyd Service Desk Specialist Lauri Walker Service Desk Specialist Tara Taylor
More informationStudy of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis
Research Article Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis RR. Pawar*, ML. Pardeshi and BB. Ghongane Department of Pharmacology, B.J. Medical
More information4/25/2016. Transplant Journey. Objectives. Reason for Transplantation at Mayo Clinic. Mayo Clinic Model of Care
Transplant Journey Lynette Fix, RN, BAN, CCTC Objectives Identify key components of transplant evaluation process Identify the patient follow-up process Describe diseases indicated for transplantation
More informationHow does a kidney transplant differ from dialysis?
TA L K I N G A B O U T T R A N S P L A N TAT I O N Frequently Asked Questions about Kidney Transplant Evaluation and Listing If your kidneys have stopped working properly, or may stop working soon, you
More informationTACROLIMUS LEVELS IN LIVER TRANSPLANT; INDIAN STUDY
TACROLIMUS LEVELS IN LIVER TRANSPLANT; INDIAN STUDY PRADEEP NAIK*, DHARMESH KAPOOR**, DCS REDDY** *Dept. of Biochemistry, ** Dept. of Hepatology Global Hospital, lakdi ka pool, Hyderabad, 500004. Introduction:
More informationGaming the Liver Transplant Market. Jason Snyder. UCLA Anderson School of Management
Gaming the Liver Transplant Market Jason Snyder UCLA Anderson School of Management January 14 th, 2009 1 Abstract: This paper examines the impact of a reform designed to curtail the strategic manipulation
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationClinical Case n. 3 Massimo Puoti AO Ospedale Niguarda Ca Granda Milano, Italy
Clinical Case n. 3 Massimo Puoti AO Ospedale Niguarda Ca Granda Milano, Italy Disclosures Member of advisory boards &/or speaker in own events &/or investigator in RCT &/or research grants &/or teacher
More informationLiver Failure. Nora Aziz. www.3bv.org. Bones, Brains & Blood Vessels
Liver Failure Nora Aziz www.3bv.org Bones, Brains & Blood Vessels Severe deterioration in liver function Looses ability to regenerate/repair decompensated Liver extensively damaged before it fails Equal
More informationACUTE HEPATIC FAILURE (Prognosis & Liver transplantation)
ACUTE HEPATIC FAILURE (Prognosis & Liver transplantation) DR.NASSER E.DARYANI PROFESSOR OF TEHRAN MEDICAL UNIVERSITY Definition Complex syndrome of acute liver injury with INR>1.5 and any degree of encephalopathy
More informationModifications to How New Donor Information Received Post-Transplant is Reported to Recipient Centers
Modifications to How New Donor Information Received Post-Transplant is Reported to Recipient Centers Sponsoring Committee Ad Hoc Disease Transmission Advisory Public Comment: 2016-January Board Date: 2016-June
More informationLIVING KIDNEY DONATION
LIVING KIDNEY DONATION 1 THE MICHIGAN DIFFERENCE Why Living Donation? As of May 2011, there were close to 2,500 individuals on the waiting list for a kidney transplant in the state of Michigan and more
More informationQUESTIONS FOR LEUVEN CASE (B)
Brandeis University The Heller School for Social Policy & Management QUESTIONS FOR LEUVEN CASE (B) Jon Chilingerian, Ph.D Email: chilinge@brandeis.edu Managing Clinics, Care Processes and the Physics of
More informationSchool-age child 5-1 THE BLOOD
C A S E S T U D Y 5 : School-age child Adapted from Thomson Delmar Learning s Case Study Series: Pediatrics, by Bonita E. Broyles, RN, BSN, MA, PhD. Copyright 2006 Thomson Delmar Learning, Clifton Park,
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationMaking ACOs Work for You. By Gregory A Culley, MD
Making ACOs Work for You By Gregory A Culley, MD The continuing increase in medical costs has created a renewed interest in changing the payment method for healthcare providers. In some ways, everything
More informationQuality measures in healthcare
Quality measures in healthcare Henri Leleu Performance of healthcare systems (WHO 2000) Health Disability-adjusted life expectancy Responsiveness Respect of persons Client orientation Fairness France #1
More informationTerminal illness pricing considerations. Steve Varney
pricing considerations Presenters Brad Louis Steve Varney AGENDA 1. Current Status 2. Estimating TI Cost 3. Data and Critical Assumptions 4. Estimated Costs 5. Conclusions 1: CURRENT STATUS Terminal Illness
More informationPREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL
Pennsylvania PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL Pennsylvania Hepatitis C Virus (HCV) in Pennsylvania Prevalence + + Although state-wide data were unavailable,
More informationOneMatch National. Sue Smith, Executive Director, Stem Cells 2011-11- 04
OneMatch National Public Cord Blood Bank Blood Matters 2011 Sue Smith, Executive Director, Stem Cells 2011-11- 04 No Disclosures To Declare The presenter does not have any involvement with the industry
More informationThe Natural History of Hepatitis C Cirrhosis After Liver Transplantation
LIVER TRANSPLANTATION 15:1063-1071, 2009 ORIGINAL ARTICLE The Natural History of Hepatitis C Cirrhosis After Liver Transplantation Roberto J. Firpi,* Virginia Clark,* Consuelo Soldevila-Pico, Giuseppe
More informationChapter 24: Renal Transplantation in the Older Adult
Chapter 24: Renal Transplantation in the Older Adult Erica L. Hartmann Abdominal Organ Transplant Program, Department of Internal Medicine-Nephrology, Wake Forest University Health Sciences, Winston-Salem,
More informationHemophilia Care. Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future?
Future of This chapter provides answers to these questions: Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future? Will the
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationTransplantUpdate. A Report From Baylor Regional Transplant Institute Volume 2 Number 1
TransplantUpdate A Report From Baylor Regional Transplant Institute Volume 2 Number 1 Treatment of Ascites 2 Ascites the accumulation of fluid in the abdominal cavity is the most common complication of
More informationDepartment of Veterans Affairs VHA DIRECTIVE 2012-018 Veterans Health Administration Washington, DC 20420 July 9, 2012
Department of Veterans Affairs VHA DIRECTIVE 2012-018 Veterans Health Administration Washington, DC 20420 SOLID ORGAN AND BONE MARROW TRANSPLANTATION 1. PURPOSE: This Veterans Health Administration (VHA)
More informationTransplant Report. UMassMemorial Medical Center A Member of UMass Memorial Health Care
Transplant Report UMassMemorial Medical Center A Member of UMass Memorial Health Care A Message from the Chief Dear Colleague: In recent years, UMass Memorial Medical Center has made significant strides
More informationAlcoholic hepatitis describes liver inflammation caused by drinking alcohol.
visited on Page 1 of 9 Diseases and Conditions Alcoholic hepatitis By Mayo Clinic Staff Alcoholic hepatitis describes liver inflammation caused by drinking alcohol. Though alcoholic hepatitis is most likely
More informationRed blood cell transfusions in the Netherlands Towards (very) low use
Red blood cell transfusions in the Netherlands Towards (very) low use Marian G.J. van Kraaij, MD PhD hematologist/ transfusion medicine specialist Director Dept Transfusion Medicine Sanquin Blood Supply,
More informationArticle from: Health Watch. January 2015 Issue 77
Article from: Health Watch January 2015 Issue 77 A Comparison Between the ACA Exchange and Medicare Risk Adjustment Programs By Kurt Wrobel With the increasing movement to individual health insurance products
More informationUnderstanding Medicare Enrollment Periods
TIP SHEET Understanding Medicare Enrollment Periods Revised November 2011 Knowing when you can get Medicare can sometimes be confusing. This tip sheet is designed to help you learn more about enrollment
More information